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Stroke is a one of the leading causes of morbidity and mortality in the world. Carotid atherosclerosis is recognized as an important
factor in stroke pathophysiology and represents a key target in stroke prevention; multiple treatment modalities have been
developed to battle this disease. Multiple randomized trials have shown the eﬃcacy of carotid endarterectomy in secondary stroke
prevention. Carotid stenting, a newer treatment option, presents a less invasive alternative to the surgical intervention on carotid
arteries. Advances in medical therapy have also enabled further risk reduction in the overall incidence of stroke. Despite numerous
trials and decades of clinical research, the optimal management of symptomatic and asymptomatic carotid disease remains
controversial. We will attempt to highlight some of the pivotal trials already completed, discuss the current controversies and
complexities in the treatment decision-making, and postulate on what likely lies ahead. This paper will highlight the complexities
of decision-making optimal treatment recommendations for patients with symptomatic and asymptomatic carotid stenosis.
1.Introduction
Stroke is a major, well-recognized cause of morbidity and
mortality around the world. Extracranial carotid athero-
sclerosis with the resulting atherothromboembolism may
account for up to 20% of ischemic strokes [1]. Carotid
stenosis may manifest itself in many diﬀerent clinical stroke
syndromes, from asymptomatic carotid disease to a TIA
aﬀecting the eye (amarousis fugax) or the brain to an
ischemic stroke in the cerebral territory supplied by the
vessel. Recently, cognitive impairment as a result of carotid
stenosis has also been proposed [2].
Multiple treatments have been shown eﬃcacious in
treating carotid disease. Carotid endarterectomy (CEA) has
been shown to be eﬀective in signiﬁcantly reducing the
risk of recurrent stroke emanating from that pathological
nidus [3, 4]. Angioplasty and stenting of the carotid origin
have developed and evolved as a less invasive alternative
to surgery, initially employed in patients with high sur-
gical comorbidities. Multiple trials have been conducted
comparing the two techniques in various subpopulations
with often conﬂicting results. The importance of the best
medical treatment cannot be overstated, as more advanced
pharmacological agents and more stringent management
of various risk factors of atherosclerosis have led to an
overall decline in the incidence of stroke. This has altered
the risk-beneﬁt analysis of any invasive procedures which
carry a nontrivial complication rate of their own. Despite
numerous trials and decades of clinical research, the optimal
management of symptomatic and asymptomatic carotid
disease remains controversial. We will attempt to highlight
some of the pivotal trials already completed, discuss the
current controversies and complexities in the treatment
decision-making, and postulate on what likely lies ahead.2 Stroke Research and Treatment
2. Risk Factors
Risk factors for the risk of stroke in the presence of carotid
stenosis are age, hypertension, coronary heart disease, irreg-
ular and ulcerated plaque morphology, absence of collateral
ﬂow, impaired cerebral reactivity, previous stroke or TIA,
and microembolic signals observed on Transcranial Doppler
(TCD) [5, 6].
Meta-analysis including 23,706 participants [7]o ff o u r
population-based studies (Malm¨ o Diet and Cancer Study,
Tromsø, Carotid Atherosclerosis Progression Study, and Car-
diovascular Health Study) showed the prevalence of severe
asymptomatic carotid stenosis in the general population to
be up to 3.1%. It has been shown that the risk of stroke
increases with the degree of stenosis (from less than 1%
p e ry e a rf o ra<80% stenosis to 4.8% per year for a >90%
stenosis).
The risk of stroke in the target vascular territory also
rises with higher degree of symptomatic carotid stenosis
(Hazard ratio (HR) 1.18 per 10% increase in stenosis; 95%
conﬁdence interval (CI) 1.10–1.25) [3, 4, 8]. Paradoxically,
patients with ICAs severely narrowed or nearly collapsed
due to markedly reduced poststenotic blood ﬂow (pseudo-
occlusion, near occlusion) have a relatively lower risk of
stroke on best medical treatment alone (HR = 0.49; CI 0.19–
1.24) compared to vessels with moderate degree of stenosis
[9, 10]. It has been shown that the risk of stroke ipsilateral
to ICA stenosis is greater in patients with recent neurological
symptoms of ischemia in that vascular target artery [11, 12].
These preceding neurological symptoms have been stratiﬁed
in the likelihood of subsequent ipsilateral stroke: major
stroke (HR = 2.54; 95% CI 1.48–4.35), multiple TIAs (HR =
2.05; 95% CI 0.16–3.60), minor stroke (HR = 1.82; 95% CI
0.99–3.34), single TIA (HR = 1.41; 95% CI 0.75–2.66), and
ocular events (HR = 1.0) [8].
Plaque instability, another important risk factor, is
characterized by a thin ﬁbrous cap, large lipid core, reduced
smooth muscle content, and a high macrophage density.
Studies have shown that the irregular morphology or
ulceration of the plaque carries an increased risk of a clinical
event (HR = 2.03; CI 1.31–3.14) [8]. A thrombotic cascade
occursprimarilywhenthethrombogeniccenteroftheplaque
is exposed to the bloodstream carrying clotting factors. The
spike in the risk of stroke recurrence in the days and weeks
after an ischemic event is likely the consequence of an
unstable atherosclerotic plaque, and the rapid decline in risk
over the subsequent months likely reﬂects the healing and
stabilization of the said lesion and improved collateral blood
ﬂow to the ipsilateral cerebral hemisphere [10].
3. TransientIschemic Attacks
Transient ischemic attack (TIA) is a brief episode of neuro-
logicaldysfunctionresultingfromfocalcerebralischemianot
associated with permanent cerebral infarction [13]. Among
patients who present with stroke, the prevalence of prior
TIA has been reported to range from 7% to 40%, depending
on factors such as how a TIA is deﬁned, which stroke
subtypes are evaluated, and whether the study is hospital or
populationbased[14,15].Inthepopulation-basedNorthern
Manhattan Stroke Study, the prevalence of preceding TIAs
among those with ﬁrst ischemic stroke was 8.7% [16], with
the majority of TIA occurring within 30 days of the patient’s
ﬁrst ischemic stroke.
It has long been recognized that TIA can portend stroke
[17], with short-term stroke risk being particularly high,
exceeding10%in90days[14,18–22]andstudiesconﬁrmthe
elevation of that risk into the long term [23–25]. The timing
of a TIA before stroke is highly time dependent, with studies
showing 17% occurring on the day of the stroke, 9% within
the previous day, and another 43% within the previous week
of the index event [18, 26–28].
Several score systems based on clinical characteristics,
like California score and the ABCD score, help to stratify
patientsintodiﬀeringrisktiers[29].ThenewerABCD2 score
was derived to provide a more robust prediction standard
and incorporates elements from both prior scores [29]. In
addition, patients with severe extra- or intracranial stenosis
carry a particularly high risk of disease recurrence [30].
Observational studies showed that urgent evaluation at
a TIA clinic and immediate initiation of treatment reduces
stroke risk after TIA [31, 32]. It has been shown that early
management of TIA patients in a stroke unit leads to speciﬁc
treatments in a signiﬁcant proportion of cases [33].
4. DiagnosticEvaluation
Imaging of the brain and its supplying vessels is crucial in
the treatment of patients with stroke or TIA. During the
initial assessment, radiological studies distinguish ischemic
stroke from intracranial hemorrhage and stroke mimics and
are used to identify the penumbra and vessel occlusion,
thus guiding emergent stroke care. In the acute setting,
radiological studies often point to the subtype and etiology
of stroke and can be utilized to predict outcome. Presence
of a diﬀusion-weighted imaging (DWI) lesion and a vessel
occlusion on a magnetic resonance image (MRI) among
patients presenting acutely with a transient clinical symp-
toms or a minor stroke is predictive of an increased risk for
future stroke and functional dependence [34]. For example,
in the North Dublin TIA Study [35]o f4 4 5c o n ﬁ r m e dT I A
cases, carotid stenosis predicted 90-day stroke (HR = 2.56;
CI 1.27–5.15, P = 0.003). Risk of stroke rose with increasing
gradeofcarotidstenosis,rangingfrom5.4%(CI3.3%–8.7%)
with <50% stenosis to 17.2% (CI 9.7%–29.7%) with severe
stenosis/occlusion (HR = 3.3; CI 1.5–7.4, P = 0.002). Thus,
prompt advanced vascular imaging is important for eﬀective
treatment in secondary stroke prevention. It has been shown
that vascular evaluation assessment does identify the site and
cause of arterial obstruction, and the patients at high risk of
stroke or stroke recurrence [36–40].
Carotid ultrasound provides reliable assessment of the
carotid bifurcation with high sensitivity and speciﬁcity [41,
42]. It is fast, inexpensive, and widely available. In TIA
patients,carotidduplexandTCDperformedwithin24hours
of symptoms revealed a threefold greater risk for stroke in
the next 90 days in those with moderate to severe extra- orStroke Research and Treatment 3
intracranial carotid stenosis compared to patients with no
such ﬁndings [43].
TCD provides noninvasive monitoring of intracranial
stenosis [37], with a positive predictive value (PPV) of 36%
and, negative predictive value (NPV) of 86% [44]. The
high NPV and the lower PPV reﬂect the low prevalence of
intracranial stenosis in Caucasians [6], with higher rates in
other ethnic groups.
TCD can also detect microembolic signals (MESs) seen
with extracranial or cardiac sources of emboli. A large
number of MESs on TCD is a marker of risk in patients
withembolifromthecarotidorigin,promptingresearchinto
optimal strategies for medical treatment and the timing of
endarterectomy in those with an extracranial carotid disease
[6]. In a cohort of patients unselected for stroke mechanism,
MESs were more common in patients with large-artery
occlusive disease and were more prevalent in patients treated
with anticoagulation rather than antiplatelet agents [5].
Theadvancementandreﬁnementofcomputedtomogra-
phy over the past quarter century has made it powerful tool
for the visualization of the vascular system. It can provide
highly detailed images of the carotid artery, with higher
sensitivity and speciﬁcity than ultrasound, but does require
patients to undergo radiation and contrast exposure, fares
poorly with heavily calciﬁed lesions, and involves some post
acquisition image processing. Magnetic resonance imaging
(MRA) has also seen an evolution in image resolution and
specialized sequencing, and the modality can distinguish not
only the anatomy of the vessel but also the composition
of the atherosclerotic plaque with remarkable detail. MRI
scanners are less widespread, and the study can overestimate
the degree and morphology of high-grade stenosis. MRA
with contrast provides a more accurate assessment of the
vasculature image, but does involve gadolinium, which
carriesadditionalrisks.Moreover,certainpatientshavemetal
implantsorpacemakers,makingthemineligibleforscanning
by this technique. Cerebral angiography is still considered
“the gold standard” for evaluating the cerebrovascular
system and its collaterals. However, it is expensive and
has a signiﬁcant radiation exposure and a discrete chance
of retroperitoneal hematoma, vessel perforation, or distal
emboli.
Asensibleandstepwisenonemergentdiagnosticwork-up
would usually entail an initial carotid duplex for screening
purposes. If the stenosis is less than 50%, no further imaging
is likely needed. If the carotid duplex comes back as >50%
(and certainly >70%), CTA or MRA should be considered
for more detailed plaque characterization. At that point and
based on patient’s presenting symptomatology, cerebrovas-
cular and overall health and available resources, diagnos-
tic/therapeutic cerebral angiogram, surgical intervention, or
continued medical management can be undertaken.
5. Carotid Endarterectomy
Carotid endarterectomy is a surgical procedure of removing
the plaque from the carotid artery, thus reducing the risk of
stroke by enlarging the lumen and by removing a possible
nidus of emboli. The anticipated beneﬁt of treatment in
asymptomatic patients with carotid stenosis is derived from
several clinical trials.
6.Asymptomatic CarotidStenosis
In Asymptomatic Carotid Atherosclerosis Study (ACAS)
[45], patients with asymptomatic carotid artery stenosis
of 60% or greater, deﬁned by angiography or Doppler
evaluation using local laboratory diagnostic criteria, were
randomized to CEA or best medical management. After a
median followup of 2.7 years, the aggregate risk over 5 years
for ipsilateral stroke and any perioperative stroke or death
was estimated to be 5.1% for surgical patients and 11.0%
for patients treated medically (aggregate risk reduction of
53%; absolute risk reduction of approximately 1% per year).
Thisnetbeneﬁtwasdependentuponcarotidendarterectomy
being performed with less than 3% perioperative morbidity
and mortality.
The Asymptomatic Carotid Surgery Trial (ACST) [46]
randomized asymptomatic patients with signiﬁcant carotid
stenosis according to Doppler criteria, to immediate CEA
or indeﬁnite deferral of surgical intervention. The mean
followup was 3.4 years. The cumulative 5-year risks of
surgical versus medical treatment were 6% versus 12% for
all strokes, 4% versus 6% for fatal or disabling strokes, and
2% versus 4% for only fatal strokes, respectively. Subgroup-
speciﬁc analyses found no signiﬁcant heterogeneity in the
perioperative risk or in the long-term postoperative beneﬁts.
A meta-analysis of three trials [47] reported that despite
about a 3% perioperative stroke or death rate, carotid
endarterectomy for asymptomatic carotid stenosis reduces
theriskofipsilateralstroke,andanystroke,byapproximately
30% over 3 years. For the outcome of any stroke or death,
there was a nonsigniﬁcant trend toward fewer events in
the CEA group. In subgroup analysis, CEA appeared more
b e n e ﬁ c i a li nm e nt h a ni nw o m e na n dm o r ei ny o u n g e r
patients than in older patients, although the data for
age eﬀect was less convincing. There was no statistically
signiﬁcant diﬀerence between the treatment eﬀect estimates
in patients with diﬀerent grades of signiﬁcant stenosis, but
the analysis may not have been suﬃciently powered.
In Asymptomatic Carotid Emboli Study (ACES), a pros-
pective observational study in patients with asymptomatic
carotid stenosis of at least 70%, followed up for 2 years, and
monitored for 1 hour at 6, 12, and 18 months, HR for the
risk of ipsilateral stroke, or TIA in patients with embolic
signals compared with those without was 2.54 (CI 1.20–
5.36; P = 0.015) [48]. For ipsilateral stroke, alone, HR was
5.57 (CI 1.61–19.32; P = 0.007). Therefore, detection of
embolization on TCD may be used to help stratify patients
with asymptomatic carotid stenosis in a higher and lower
vascular event risk groups.
Trials of carotid surgery for asymptomatic carotid ste-
nosis have concluded that although surgery reduces the
incidence of ipsilateral stroke (RR 0.47–0.54) and any stroke,
the absolute beneﬁt is small (approximately 1% per annum)
[45, 46, 49], whereas the perioperative stroke or death4 Stroke Research and Treatment
rate is 3%. Medical management is the most appropriate
option for most asymptomatic subjects; only centers with
a perioperative complication rate of 3% or less should
contemplate surgery. Patients with a high risk of stroke (men
with stenosis of more than 80% and a life expectancy of
more than 5 years) may derive some beneﬁt from surgery in
appropriate centers [46, 47].
7. Symptomatic CarotidStenosis
For symptomatic carotids, the ECSCT and NASCET [9, 28]
results established CEA as the treatment of choice for mod-
erate and severe carotid artery stenosis as a secondary stroke
prevention measure. The most important periprocedural
risks of CEA are death (about 1%) and stroke (about 5%)
[9, 28]. From a pooled analysis of data from the three
largest RCTs of surgery for symptomatic carotid stenosis
[50], CEA reduced the 5-year absolute risk of any stroke
or death in patients with 50–69% stenosis, according to
angiographic NASCET criteria (which consist of measuring
the lumen at the point of the greatest stenosis divided
by the diameter of the carotid beyond the carotid bulb)
(absolute risk reduction (ARR) 7.8%, CI 3.1–12.5), and was
highly beneﬁcial in patients with 70–99% stenosis (15.3%,
CI 9.8–20.7), but showed no beneﬁt in patients with a
near occlusion. Quantitatively similar results were seen for
disabling stroke [50]. CEA, therefore, proved to be beneﬁcial
in stenosis more than 50% according to NASCET criteria,
which are equivalent to 65% stenosis by ECST criteria.
In ECST trial, CEA reduced the risk of recurrent TIAs in
patients with a near occlusion (ARR 15%, P = 0.007).
While the degree of stenosis is a major determinant of
beneﬁt from CEA, there are other clinical characteristics
that inﬂuence the risks and beneﬁts of surgery. Subgroup
analyses of pooled data from the large RCTs [51] showed
the greatest beneﬁt from CEA in men, patients aged ≥75
years, and patients randomized within 2 weeks after their
last ischemic event. Both ECST and NASCET showed that
for patients with ≥50% ICA stenosis, the number needed to
treat (NNT) by CEA to prevent one ipsilateral stroke in 5
years was 9 for men versus 36 for women, 5 for age ≥75 years
versus 18 for age <65 years, and 5 for patients randomized
within 2 weeks after the last ischemic event versus 125 for
patients randomized >12 weeks. Women had a lower risk of
ipsilateral ischemic stroke on medical treatment and a higher
o p e r a t i v er i s ki nc o m p a r i s o nt om e n[ 52]. CEA was more
beneﬁcial in women with ≥70% stenosis, but not in women
with 50–69% stenosis. At the same time, CEA reduced the 5-
year ARR by 8.0% CI 3.4–12.5 in men with 50–69% stenosis.
This sex diﬀerence was statistically signiﬁcant even when the
analysis of the interaction was conﬁned to the group of 50–
69% stenosis [52].
8. CEA SurgicalConsiderations
CEA has been established as “the gold standard” for
carotid stenosis treatments for many years, yet the surgical
techniques of performing the procedure continue to evolve.
In traditional endarterectomy, the plaque is removed via
a longitudinal arteriotomy. Another technical variant is
eversion endarterectomy, which employs a transverse arte-
riotomy and reimplantation of the carotid artery. There was
no signiﬁcant diﬀerence in the rates of perioperative stroke,
stroke, death, or local complication rates in a review of ﬁve
RCTs comparing eversion and conventional endarterectomy
performed either with primary closure or patch angioplasty
[53]. To reduce the risk of restenosis, many surgeons use
a patch of autologous vein or synthetic material to close
the artery and to enlarge the lumen. Although the patch
increases the surgery time and complication rate, it was
associated with a 60% reduction in the perioperative risk of
stroke or death during the postoperative period and long-
term followup, 85% reduction in the risk of perioperative
arterial occlusion, and 80% reduction in the risk of vessel
restenosis during long-term followup. Although some sur-
geons routinely insert a temporary intralumenal shunt [54],
the number of patients who need shunting with diﬀerent
shunting policies has been too small, and the results of
clinical studies inconclusive [55].
CEA was traditionally performed under general anes-
thesia (GA), but surgery under local anesthesia (LA) is
becoming more widespread. While a systematic review of
seven small randomized trials showed the use of LA to be
associated with a borderline statistically signiﬁcant trend
towards a reduced risk of operative death, no evidence of
a reduction in risk of perioperative stroke was found [56].
A large multicenter randomized trial has shown no major
diﬀerence in operative risk of stroke or death combined
(risk ratio for LA versus GA RR = 0.94; CI 0.70–1.27)
[57]. The anesthesiologist and surgeon, in consultation with
the patient, should determine the method of appropriate
anesthesia [58]. For patients with a contralateral carotid
occlusion, LA may oﬀer some beneﬁt.
9.CarotidStenting
Carotid angioplasty and stenting (CAS) was developed to
be a less invasive and involved procedure compared to
carotid endarterectomy. It has emerged as an alternative for
patients who are considered to have high surgical risks due
to medical comorbidities or anatomical high-risk features.
Sinceitsdevelopmentovertwentyyearsago,thetechniqueof
endovascular carotid revascularization has been undergoing
a continuous maturation process due to the shift from the
initial use of balloon expandable stents to self-expanding
stents, the introduction of and continuously expanding
array of embolic protection devices (EPDs), and increasing
operator experience.
The procedure is usually done under local anesthetic,
with the subsequent expectation of less nerve injuries,
venous thromboembolisms, and myocardial infarctions—
all well-known clinical costs of going to the operating
room. CAS also carries some potential disadvantages such
as arterial dissection, dislocation of atherothrombotic debris
and embolization to the brain or eye, late embolization
due to thrombus formation on the damaged plaque, andStroke Research and Treatment 5
bradycardia and hypotension as a result of carotid sinus
stimulation. Local complications at the site of arterial
cannulation such as hematoma and aneurysm formation
may also occur. Rarely, the stent may erode through the
arterialwallorfractureupondeployment.Inthelongerterm,
restenosis appears to be more common after stenting than
after endarterectomy.
Several trials have compared CAS and CEA in secondary
stroke prevention, mostly in patients lacking high surgical-
risk [49, 59–65]. Most studies were designed to assess the
noninferiority of stenting compared to endarterectomy with
regard to the early risks of the procedures. None of these
studies were adequately powered to show the noninferiority
(or superiority) of stenting looking at both the early risks
and late beneﬁts of these techniques. Initially, locating
studies with the desired target populations has also proved
a challenge. For example, The Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterectomy
(SAPPHIRE) trial included more than 70% of asymptomatic
patients, and therefore should not be used for decisions
about secondary prevention [49]. In Carotid and Vertebral
Artery Transluminal Angioplasty Study (CAVATAS), on the
other hand, the majority of the patients in the endovascular
group underwent angioplasty, and only 26% were treated
with a stent [65].
The comparison of CEA and CAS has produced many
diﬀerent (and often contradictory) results. Stent-protected
angioplasty versus carotid endarterectomy in symptomatic
patients (SPACE) marginally failed to prove the noninferi-
ority of CAS compared to CEA with the endpoint being
ipsilateral stroke or death up to post-op day 30. The event
rates for 1,200 enrolled patients were 6.8% for CAS and 6.3%
for CEA patients (absolute diﬀerence 0.5%; CI −1.9 +2.9%;
P = 0.09) [66]. The Endarterectomy versus Stenting in
Patients with Symptomatic Severe Carotid Stenosis (EVA3S)
trial was stopped prematurely after the inclusion of 527
patients because of safety concerns and a lack of eﬃcacy. The
RR of any stroke or death after CAS, compared with CEA,
was 2.5 CI 1.2–5.1 [59].
The Stenting and Angioplasty with Protection in Patients
at High Risk for Endarterectomy trial (SAPPHIRE) [61]
was one of the ﬁrst trials comparing carotid stenting (CAS)
(with the use of an emboliprotection device) to CEA in
patients considered at high surgical risk for CEA. Patients
wereeligibleiftheyeitherhadasymptomaticstenosisof50%
orgreateroranasymptomaticstenosisof80%orgreater.The
primary end point of the trial was the cumulative incidence
of death, stroke, or myocardial infarction with 30 days after
the procedure or death or ipsilateral stroke between 31 days
and 1 year. The primary end point occurred in 20 patients
(12%) in the CAS group and in 32 patients (20%) in the
CEA cohort. For patients with asymptomatic lesions, the
cumulative incidence of the primary end point at 1 year
was lower among those who were treated with CAS (10%)
than who underwent a CEA (22%). In the periprocedural
period,thecumulativeincidenceofdeath,myocardialinfarc-
tion, or stroke among patients with asymptomatic carotid
artery stenosis was 5% among those who received a stent,
as compared to 10% among those who underwent a CEA.
The SAPPHIRE trial was one of the ﬁrst trials to select
high-risk patients with medical comorbidities (these criteria
were the basis of exclusion criteria for the NASCET/ACAS
trials). The major adverse events (death, stroke, and MI) at
1 year were 12.2% in the CAS group compared to 20.1% for
CEA (P = 0.053). The trial did not include a best medical
treatment arm and therefore failed to answer a question of
whatwillhappentothesurgicalhigh-riskCEApatientifthey
were to receive maximal medical treatment.
The International Carotid Stenting Study (ICSS) trial
[67] was a randomized, double-blinded study comparing
CAS and CEA in patients with symptomatic carotid stenosis
ofgreaterthan50%within6monthspriortorandomization.
Betweenrandomisationand120days,therewere34(Kaplan-
Meier estimate 4.0%) events of disabling stroke or death
in the stenting group compared with 27 (3.2%) events in
the endarterectomy group (HR = 1.28, CI 0.77–2.11). The
incidence of stroke, death, or periprocedural myocardial
infarction was 8.5% in the stenting group compared with
5.2%intheendarterectomygroup(72versus44events;HR=
1.69, CI 1.16–2.45, P = 0.006). Risks of any stroke (65 versus
35 events; HR = 1.92, CI 1.27–2.89) and all-cause death (19
versus seven events; HR = 2.76, CI 1.16–6.56) were higher
in the stenting group than in the endarterectomy group.
Three procedural myocardial infarctions were recorded in
the stenting group, all of which were fatal, compared with
four, all nonfatal, in the endarterectomy group. There was
one event of cranial nerve palsy in the stenting group
compared with 45 in the endarterectomy group. There were
also fewer hematomas of any severity in the stenting group
than in the endarterectomy group (31 versus 50 events;
P = 0.02). A magnetic-resonance-imaging (MRI) substudy
was carried out at 5 ICSS centers, with scans analysis being
performed blinded to the choice of treatment [68]. New
ischemia was found in about half of CAS patients versus
about 15% of CEA patients. On followup imaging 4 to 6
weeks later, FLAIR was abnormal at the site of early ischemia
in 30% of patients after CAS versus 8% of patients after CEA,
a result that was also highly signiﬁcant.
Subgroups analyses from RCTs suggest some hetero-
geneity of risk between stenting and endarterectomy. In
particular,theexcessriskassociatedwithstentingwasgreater
in patients aged 70 years or older [62, 63]. However,
owing to the drawbacks of post hoc analysis such as low
statistical power and the risk of chance ﬁndings, these
subgroup analyses should be interpreted with caution. The
best evidence of subgroup treatment eﬀect interaction will
be obtained from a planned combined analysis of individual
patient data from current larger trials that compare stenting
versus endarterectomy.
In various RCTs, the risk of ipsilateral stroke beyond the
perioperative period was low (<1% per year) and similar
in both the stenting and endarterectomy groups, which
stronglysuggeststhatstentingisaseﬀectiveassurgeryforthe
medium-term prevention of ipsilateral stroke—at least up to
4 years after the procedures [49, 62, 65, 69]. As the incidence
of recurrent carotid stenosis may be signiﬁcantly higher after6 Stroke Research and Treatment
CAScomparedtoCEA[70],thereisaneedtoassessthelong-
term eﬀects of carotid stenting, and particularly the long-
term incidence of restenosis.
After analyzing the various comparison studies, CAS
has not been shown to be as safe as CEA in patients with
symptomatic carotid artery stenosis in RCTs. The recent
meta-analyses [66, 71, 72] of RCTs that compared CAS and
CEA treatment of patients with mainly symptomatic carotid
artery stenosis indicated that patients who received CAS had
a signiﬁcantly increased risk of 30-day mortality or stroke
compared with patients who received CEA (odds ratio (OR)
1.60; CI 1.26–2.01) and concluded that CEA should remain
the ﬁrst-line intervention in “standard risk,” symptomatic
patients.
What about the patients who are not “standard risk” and
who cannot tolerate surgery? The registry of high-surgical
risk patients undergoing CAS (recruited to postmarketing
surveillance in the EXACT and CAPTURE trials) has shown
diﬀerent outcomes [70]. In a cohort of 6320 patients, 12%
who had suﬀered stroke or TIA 6 months prior to CAS,
a subgroup analysis was performed, stratiﬁed for age. The
30-day rate of death/stroke in 589 patients aged <80 years
was 5.3% (CI 3.6–7.4), compared to 10% in 172 patients
aged >80 years (CI 3.3–16). The authors concluded that
CAS had demonstrated real-world outcomes consistent with
established American Heart Association (AHA) guidelines in
symptomatic patients and should be a viable alternative to
CEA in this “high-risk” cohort. There are some questions
that need to be answered before relying on these results in
recommending CAS to patients who are at high risk for CEA
[73]. The low procedural risk observed in nonoctogenarian
patientsintheamalgamatedregistrymustbemaintainedand
regularly audited; if it exceeds 8%, the therapeutic beneﬁt
will likely shift away from intervention. The etiology of
the carotid stenosis is also important in interpreting the
studies’ restenosis results: primary atherosclerotic disease or
nonatheroscleroticdisease(e.g.,radiationarteritis,restenosis
after CEA, etc.) are distinct disease processes and likely
behave diﬀerently after stenting. The post hoc analysis from
the Acculink for Revascularization of Carotids in High-Risk
Patients(ARCHeR)CASRegistryshowedthatthe30-dayrisk
following CAS in patients with nonatherosclerotic disease
was 14 times lower than in their atherosclerotic counterparts
[74]. Clearly, what treatment is best for which particular
patient is not all that clear.
Furthermore, Carotid Revascularization Endarterectomy
versus Stenting Trial (CREST) [75] was the only RCT
comparing CAS and CEA in patients with symptomatic
and asymptomatic carotid stenosis that showed equal risk
of the composite primary outcome of stroke, myocardial
infarction, or death. During the periprocedural period, there
was a higher risk of stroke with stenting and a higher risk
of myocardial infarction with endarterectomy. Recent sub-
group analysis showed sex diﬀerences of primary endpoints
did exist: women fared worse with CAS compared to CEA,
while men did equally well with either procedure [76].
Another study compared subgroups of patients who had
suﬀered an MI (clinical or biochemical) and found MIs to be
more common in CEA and to be independently associated
to increased future mortality [77]. Given the main ﬁnding of
therapeutic equivalence between CAS and CEA, the obvious
questions arose about the discrepancies between CREST and
the preceding trials.
There are certain key diﬀerences in trial methodology
and design. The ﬁrst important methodological diﬀerence
was operator experience across the studies [78]. Lifetime
endovascular requirements were as follows: in CAVATAS
(year 2001), 504 patients, operators had training in neuro-
radiology and angioplasty (but not necessarily in the carotid
artery), and tutor-assisted procedures were allowed; in SAP-
PHIRE (year 2004), 334 patients, procedures were submitted
to an executive review committee, CAS periprocedural death
or stroke rate had to be less than 6%, and no tutor-
assistedprocedureswereallowed;inSPACE(2006)with1200
patients, at least 25 successful CASs or assistance of a tutor
for interventionalists who have done at least 10 CAS was
required; in EVA 3S (2006), with 527 patients, operators had
to have performed at least 12 CAS cases or at least 5 carotid
stent procedures and more than 30 cases of endovascular
treatment of supra-aortic trunks, or tutor-assisted CAS was
allowed for centers not fulﬁlling minimum requirements;
in ICSS (2010) with 1710 patients, a minimum of 50 total
stenting procedures of which at least ten should be in the
carotid artery or tutor-assisted procedures were allowed for
interventionalists with insuﬃcient experience. The trend
across all of these studies was that many operators may have
had some experience with peripheral stent placement, but
that experience was not necessarily equivalent to stenting in
the carotid vasculature. As aortic arch tortuosity is emerging
asoneofthecriticalfactorsdeterminingproceduralriskwith
CAS.Lackofproofofexperiencewithcarotidcatheterization
as a prerequisite for participation as an interventionalist
across all the Europeans trials is probably the factor respon-
sible for high rates of stroke reached in these studies. In
contrast, prospective CAS registries (mentioned earlier) in
North America preceding CREST required a higher level of
experience with brachiocephalic catheterization and carotid
interventions and have reported rates of stroke that are
signiﬁcantlylessthanthosereportedintheEuropeanstudies.
CREST study (2010), with 2502 patients, was even more
rigorous and required a minimum experience of 10–30
carotid stent procedure with 0.14’ wire systems, experience
with EPD, and a documented 30-day stroke and death rate
of 6–8% [79]. In addition, after admittance into the study,
there was a required lead-in phase of up to 20 patients
designed to ensure operators had adequate experience
and acceptable complication rates prior to randomizing
patients. The standards of rigorous vetting for proceduralists
performing carotid revascularization were set by NASCET
(perioperative risk of stroke or death <6% at 30 days) and
ACAS [9, 45], in which only experienced surgeons chosen
according to strict criteria were allowed to participate. As
opposed to the stenting arm operators, carotid surgeons
in the European randomized trials of CAS versus CEA
were more experienced compared to their interventionalist
counterparts, and there were no inexperienced surgeons
allowed to perform the procedure whether or not a tutor was
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The second major protocol diﬀerence was the use or
periprocedural dual antiplatelet medications. In the ICSS
and EV-3S studies, the use of dual antiplatelet medication
was recommended but not required—in EVA-3S [59], 17%
of patients were not on dual antiplatelet medications prior
to the procedure, and nearly 15% did not have these
medications after procedure. In the CREST study, the use
of dual antiplatelet therapy was required and part of the
protocol.
The third issue was the lack of exclusion criteria for
stenting, a stark contrast to high surgical-risk criteria
precluding randomization present for the CEA arms in the
EVA-3S, ICSS, and SPACE trials. Absence of angiographic
exclusion criteria for stenting in combination with inexpe-
rienced interventionalists may have resulted in a signiﬁcant
rate of perioperative stroke and death seen in the CAS
arm in EVA-3S. In the CREST trial, rigorous angiographic
exclusion criteria such as severe tortuosity and calciﬁcation,
intraluminal, thrombi, and large, bulky plaques may explain
discrepant results. Also, ICSS, EVA-3S, and SPACE all
allowed the use of many diﬀerent types of stents and EPD,
further tipping the scales towards unfavorable outcomes,
when deployed in the hands of inexperienced operators.
Contrary, in the CREST study, the same stent and EPD
system(AcculinkstentandAccunetEPD)wasusedacrossthe
board, allowing the operator to become very familiar with
the idiosyncrasies of one single device. Moreover, the lack of
protocol in the European studies resulted in the variable use
of EPDs, while in the CREST study, the protocol required
the use of an embolic protection device in all enrolled
patients.
10. Stenting Consideration
Certain vascular and local anatomical features are consid-
ered relative contraindications depending on experience of
an interventional radiologist/neurologist/neurosurgeon and
the type of anatomical substrate for CAS. These include
complex bifurcation disease with long, multifocal lesions
or extensive aortic or brachiocephalic trunk plaque, severe
tortuosity or calciﬁcation of the aortic arch vessel, or ring-
like, heavy calciﬁcations of the carotid bifurcation. Based
on experts’ opinion and not on RCTs, CAS is indicated
in patients with contralateral laryngeal nerve palsy and
previous radical neck dissection or cervical irradiation and
with prior CEA (restenosis), because the rate of cranial
nerve injuries following surgery is higher in this subset.
Also, CAS can be oﬀered to patients with a high bifurcation
or intracranial extension of a carotid lesion, where surgical
access could be diﬃcult or to patients with a high risk
of cerebral ischemia during carotid clamping (occlusion
of the contralateral ICA and anomalies of the circle of
Willis).
Carotid stenting insymptomatic patients withastandard
risk should only be considered in high-volume CAS centers
with a 30-day risk of death/stroke as independently audited
and maintained <6% [58] and where patients are treated
without delay, preferably within 14 days. If these two caveats
cannot be achieved, the patient should be referred for CEA.
11.Extracranial-Intracranial
Anastomosis (EC-ICBypass)
About 5–10% of patients with carotid TIA or minor stroke
have occlusion of the origin of the ICA, or occasionally the
distal ICA or proximal middle cerebral artery. These lesions
can be bypassed by anastomosing a branch of the external
carotid artery, usually the superﬁcial temporal artery, via a
skull burr hole to a cortical branch of the middle cerebral
artery. Such collateral was developed to improve the blood
supply in the distal middle cerebral artery bed and to reduce
the risk of stroke or the severity of stroke. However, in an
RCT, these anastomoses between the superﬁcial temporal
andmiddlecerebralarterieswerenotbeneﬁcialinpreventing
stroke in patients with middle cerebral artery or internal
carotid artery stenosis or occlusion [80]. A recent Carotid
Occlusion Surgery Study did not show additional beneﬁts
of bypass surgery when added to medical management in
patients with symptomatic atherosclerotic internal carotid
artery occlusion [81].
12. Medical Treatment of Patients with
CarotidStenosis
In patients with carotid stenosis undergoing either primary
or secondary prevention, the treatment of risk factors such
as hypertension, diabetes mellitus, lipid, or homocysteine
metabolic disorders, as well as modiﬁcation of lifestyle,
particularly smoking cessation, are of utmost importance to
reduce both early and long-term risks of vascular events,
dementia, and death [82, 83].
Aspirin and the combination of aspirin and extended
released dipyridamole, clopidogrel, ticlopidine, and triﬂusal
have been shown to be eﬀective as antiplatelet agents in
long-term secondary prevention of ischemic stroke [84,
85]. Currently, aspirin, aspirin/extended dipyridamole, or
clopidogrel is used in clinical practice.
To date, only aspirin has been shown to be safe and
eﬀective in the acute postischemic phase (ﬁrst 48 hours) and
should be started immediately in patients with TIA/ischemic
stroke after the exclusion of brain hemorrhage and if iv-
tPA has not been given (in that case, antiplatelets are held
for the ﬁrst 24 hours). Aspirin is eﬀective in the range
of doses (30–1,300mg/day), but doses >150mg/day are
associated with more side eﬀects [86]. In the Antithrombotic
Trialists’ Collaboration, a meta-analysis of >60 aspirin trials,
the best risk reduction was found in trials using a 75-to-
150mg dose of aspirin [87–89]. In patients with a history of
aspirin-induced ulcer bleeding, aspirin in combination with
a proton-pump inhibitor was superior to clopidogrel alone
in the prevention of recurrent ulcer bleeding [90].
Clopidogrel (75mg/day) was slightly more eﬀective than
aspirin monotherapy (325mg/day) in preventing vascular
events (ischemic stroke, myocardial infarction, or vascular8 Stroke Research and Treatment
death) in the CAPRIE trial, resulting in a relative risk
reduction (RRR) of 8.7% (CI 0.3–16.5) [91]. The highest
beneﬁt of clopidogrel was seen in patients with peripheral
artery disease.
The combination of aspirin (30–300mg/day) and
extended release dipyridamole (200mg twice a day) was
shown to be more eﬀective compared with aspirin alone in
two studies [92, 93]. Combination therapy reduced vascular
events (ischemic stroke, myocardial infarction, or vascular
death) by 18% (CI 9–26). The incidence of headache, a
commonside eﬀectwithcombination therapy, canbegreatly
reduced by a slow titration of the drug.
T h eP R o F E S St r i a l[ 94]w a sah e a d - t o - h e a dc o m p a r i s o n
of clopidogrel and the combination of aspirin/extended
release dipyridamole. There was no diﬀerence in eﬃcacy
across all endpoints and all subgroups of patients. The com-
binationofaspirin/extendedreleasedipyridamoleresultedin
more intracranial bleeds and a higher dropout rate due to
headaches compared with clopidogrel (5.9 versus 0.9%).
In the MATCH trial (secondary prevention in high-risk
patients with TIA or ischemic stroke) [95] and CHARISMA
(Combined Primary and Secondary Prevention Study) trial
[96], comparison of clopidogrel or aspirin monotherapy
with its combination failed to show superiority of the
combination therapy, which had an increased bleeding rate.
The Clopidogrel and Aspirin for Reduction of Emboli in
SymptomaticCarotidStenosis(CARESS)trialshowedthatin
patients with recently symptomatic carotid stenosis combi-
nation therapy with clopidogrel and aspirin is more eﬀective
thanaspirinaloneinreducingasymptomaticembolizationin
a short-term followup [6]. The combination of clopidogrel
and aspirin cohort had fewer patients with MESs, fewer
MESs per hour, and fewer strokes compared to patients
treated with aspirin alone in the ﬁrst week after the initial
clinical presentation.
A systematic review identiﬁed four randomized tri-
als directly comparing oral anticoagulants (OAC) with
high international normalized radio (INR) (3.0–4.5) versus
antiplatelet therapy in patients with previous TIA or minor
stroke of presumed arterial origin [97]. Therapy with OAC
was associated with a signiﬁcantly higher rate of recurrent
serious vascular events (1.70, CI 1.12–2.59), with a highly
signiﬁcant increase in major bleeding complication (9.02, CI
3.91–20.84), and a signiﬁcant increase of recurrent serious
vascular events or major hemorrhage (2.30, CI 1.58–3.53)
compared with antiplatelet therapy. Therapy with OAC was
associated with a signiﬁcant increase of death from any cause
compared with antiplatelet therapy (RR 2.38, CI 1.31–4.32).
Therefore, the best medical treatment of patients with
carotid stenosis includes treatment of hypertension, diabetes
mellitus, dyslipidemia and homocysteine, metabolic disor-
ders, modiﬁcation of lifestyle, and statin and antithrombotic
therapy. High-dose statins’ use may have pleiotropic eﬀects
in acute and subacute settings. An LDL goal of <70mg/dL
has been recommended. A blood pressure regimen needs
to be carefully selected based on patient’s comorbidities
and treatment goals. It is recommended that anticoagula-
tion should not be used after noncardioembolic ischemic
strokes since high-intensity anticoagulation (INR 3.0–4.5)
is more hazardous than eﬀective compared to antiplatelet
therapy.
13. Consensus Challenges and
FutureDirections
Despite numerous RCT studies and signiﬁcant resources
devoted to studying carotid disease, a uniﬁed approach to
treatment is still far on the horizon. Many contributing
factors make consensus elusive. Professional society guide-
lines in the US (AHA/ASA) [98], New Zealand/Australia
[99], and Europe [58]a l lo ﬀer diﬀering and occasionally
contradictory recommendations based on regional studies
and policies. The Unites States government oﬀers two more
diverging opinions in its oﬃcial statements in regulating
medical devices (Food and Drug Administration) and
payments for medical services (Centers for Medicare &
Medicaid Services). Multiple medical specialties (primary
care physicians, interventionals, cardiologists, neurologists,
and vascular surgeons) are involved in treating patients
with carotid stenosis, each with its own understanding and
approach to the subject. The debate between specialties is
aliveandwell[100,101].Bestmedicaltherapy,interventional
stenting techniques, and the surgical knowhow for CEA are
rapidly evolving, constantly tipping the risk-beneﬁt ratio
in a diﬀerent direction. The prevalence of the underlying
risk factors, the carotid disease itself, and the health care
delivery are also diﬀerent than they were in the past
when some of the earlier trials were conducted. Current
best medical therapy including statins and antithrombotics
in combination with blood pressure and glucose-lowering
medications and lifestyle changes has become a powerful
tool for reduction of stroke risk in patients with carotid
stenosis. New trials comparing CAS, CEA, and best medical
therapy are once again needed, with careful selection and
followup of the patients using Transcranial Doppler, carotid
plaque morphology imaging, and vascular disease burden
stratiﬁcation [74].
14. Conclusion
Carotid stenosis accounts for up to twenty percent of
ischemic strokes and TIAs. It is a potentially preventable
cause of stroke, and therefore, its detection and management
isofanutmostimportance.Manytreatmentmodalitiesexist.
Best medical therapy including risk factor management and
antithrombotic treatmentshould be administered eﬀectively.
In appropriately selected patients, interventions on carotid
arteries should be considered in high-volume CEA and CAS
centers with low periprocedural complication rates.
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